Induction chemo-immunotherapy
Showing 1 - 25 of 9,081
Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemo)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Split-course hypo-CCRT
- +2 more
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer Center
Aug 26, 2023
Pleural Mesothelioma Trial in Italy (Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab)
Not yet recruiting
- Pleural Mesothelioma
- Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
-
Rozzano, MI, Italy
- +5 more
Nov 30, 2023
Lung Cancer, Non-small Cell Trial in Nanjing (hypofractionated radiation therapy)
Active, not recruiting
- Lung Cancer, Non-small Cell
- hypofractionated radiation therapy
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Mar 13, 2023
NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)
Recruiting
- Non-small Cell Lung Cancer
- Hypofractionated radiotherapy
- +4 more
-
Guangzhou, Guangdong, ChinaSun yat-sen university cancer center
Nov 14, 2023
Immunotherapy in Locally Advanced or Oligometastatic NSCLC
Recruiting
- Carcinoma, Non-Small-Cell Lung
- induction therapy
-
Esslingen, GermanyKlinikum Esslingen
Aug 15, 2022
HIV, Burkitt's Lymphoma Trial in Italy (Induction Phase, Consolidation Phase (on day +50), Intensification phase)
Completed
- HIV
- Burkitt's Lymphoma
- Induction Phase
- +4 more
-
Aviano (PN), Italy
- +7 more
Aug 2, 2022
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma Trial in San Francisco, Valhalla (Methotrexate, pralatraxate,,
Recruiting
- NK-Cell Lymphoma
- +2 more
- Methotrexate
- +9 more
-
San Francisco, California
- +1 more
Sep 1, 2021
Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant
Not yet recruiting
- Breast Cancer Triple Negative
- +3 more
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
May 18, 2023
Metastatic NSCLC Trial in France (Pembrolizumab before randomization, Chemotherapy, Pemetrexed)
Recruiting
- Metastatic NSCLC
- Pembrolizumab before randomization
- +3 more
-
Aix-en-Provence, France
- +37 more
Jul 26, 2022
Small Cell Lung Carcinoma Trial in Milano (Cyclic, 5-day calorie restriction, Atezolizumab)
Not yet recruiting
- Small Cell Lung Carcinoma
- Cyclic, 5-day calorie restriction
- Atezolizumab
-
Milano, ItalyFondazione IRCCS Istituto Nazionale Tumori
Jan 19, 2023
Pancreatic Cancer Trial in Sydney, Wollongong, Melbourne (Durvalumab, Oxaliplatin, Irinotecan)
Recruiting
- Pancreatic Cancer
- Durvalumab
- +5 more
-
Sydney, New South Wales, Australia
- +2 more
Oct 19, 2023
Cervical Cancer = FIGO IIB and or Lymph Node Metastases Trial (Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab),
Not yet recruiting
- Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
- Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)
- +2 more
- (no location specified)
Aug 16, 2022
NSCLC, Stage III Trial in Pavia (Durvalumab)
Recruiting
- NSCLC, Stage III
-
Pavia, ItalyFondazione IRCCS Policlinico San Matteo
Nov 9, 2021
Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Pembrolizumab injection
- +2 more
- (no location specified)
Jul 25, 2023
Merkel Cell Carcinoma Trial in Milan (Retifanlimab, Cisplatin, Etoposide)
Recruiting
- Merkel Cell Carcinoma
- Retifanlimab
- +2 more
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano
Jan 4, 2023
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III Trial (combination product, drug, procedure, radiation)
Not yet recruiting
- Lung Cancer, Nonsmall Cell
- Lung Cancer Stage III
- Nivolumab and Chemotherapy
- +3 more
- (no location specified)
Aug 15, 2023
Nasopharyngeal Carcinoma Trial in Fuzhou (without concurrent cisplatin chemo, with concurrent cisplatin chemo)
Not yet recruiting
- Nasopharyngeal Carcinoma
- without concurrent cisplatin chemotherapy
- with concurrent cisplatin chemotherapy
-
Fuzhou, Fujian, ChinaDepartment of radiation oncology, Fujian cancer hospital
Oct 18, 2023
NSCLC Stage III Trial (radiotherapy, Platinum-Based Drug, Immunotherapy)
Not yet recruiting
- Non-small Cell Lung Cancer Stage III
- radiotherapy
- +3 more
- (no location specified)
Sep 10, 2023
Cervical Cancer, Induction Chemo, Immunotherapy Trial in Tianjin (Toripalimab)
Recruiting
- Cervical Cancer
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Oct 16, 2023
Colon Tumor Trial in Hangzhou (Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody)
Not yet recruiting
- Colon Neoplasm
- Oxaliplatin
- +4 more
-
Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital of Zhejiang University School of Medi
Jun 25, 2023
Ependymoma, Medulloblastoma, Glioblastoma Trial in Augusta (Ibrutinib, Indoximod, Cyclophosphamide)
Recruiting
- Ependymoma
- +3 more
- Ibrutinib
- +3 more
-
Augusta, GeorgiaAugusta University, Georgia Cancer Center
Dec 16, 2022
Food Allergy Trial in Warsaw (High dose OIT, Low dose OIT)
Enrolling by invitation
- Food Allergy
- High dose OIT
- Low dose OIT
-
Warsaw, PolandMedical University of Warsaw
Jun 19, 2023
Bladder Cancer Trial in Switzerland (Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), Atezolizumab, Cisplatin)
Recruiting
- Bladder Cancer
- Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)
- +3 more
-
Baden, Switzerland
- +9 more
Aug 12, 2022
Head and Neck Squamous Cell Carcinoma Trial in Brescia (Niraparib)
Recruiting
- Head and Neck Squamous Cell Carcinoma
-
Brescia, ItalyAsst Degli Spedali Civili Di Brescia
Aug 3, 2022
Head Neck Cancer Trial in Beijin (anti-PD-1 or PD-L1 antibody, postoperative radiaotherapy)
Recruiting
- Head and Neck Cancer
- anti-PD-1 or PD-L1 antibody
- postoperative radiaotherapy
-
Beijin, Beijing, ChinaNational Cancer Center /National Clinical Research Center for Ca
Mar 18, 2023